Overcoming problems that impede the delivery of evidence‐based care is needed to bridge gaps between science and improving health
The benefits of lipid‐lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease, including its effect on mortality, have been recognised since the publication of the seminal 4S trial in 1994.1 Recent clinical trials of novel lipid‐lowering therapies in people taking statins have found that the lower the low‐density lipoprotein cholesterol (LDL‐C) level achieved, the lower the risk of adverse cardiovascular events.2 It is beyond doubt that people at high risk of adverse cardiovascular events, including those with a history of acute coronary syndrome, benefit most from aggressive lipid‐lowering therapy. Accordingly, the recommended LDL‐C targets are lowest for such people, and have been continually reduced in international guidelines over time.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383‐1389.
- 2. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Eng J Med 2017; 376: 1713‐1722.
- 3. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111‐188.
- 4. Alsadat N, Hyun K, Boroumand F, et al. Achieving lipid targets within 12 months of an acute coronary syndrome: an observational analysis. Med J Aust 2022; 216: 463‐468.
- 5. Gitt AK, Lautsch D, Ferrières J, et al. Cholesterol target value attainment and lipid‐lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis 2017; 266: 158‐166.
- 6. Gupta A, Thompson D, Whitehouse A, et al; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo‐Scandinavian Cardiac Outcomes Trial – Lipid‐Lowering Arm (ASCOT‐LLA): a randomised double‐blind placebo‐controlled trial and its non‐randomised non‐blind extension phase. Lancet 2017; 389: 2473‐2481.
- 7. Harris DE, Lacey A, Akbari A, et al. Achievement of European guideline‐recommended lipid levels post‐percutaneous coronary intervention: a population‐level observational cohort study. Eur J Prev Cardiol 2021; 28: 854‐861.
- 8. Billimek J, Malik S, Sorkin DH, et al. Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence following treatment intensification. Womens Health Issues 2015; 25: 6‐12.
- 9. Zhang Y, Cui Y, Shen M, et al; the medical team from Xiangya Hospital to support Hubei, China. Association of diabetes mellitus with disease severity and prognosis in COVID‐19: a retrospective cohort study. Diabetes Res Clin Pract 2020; 165: 108227.
- 10. Rodriguez F, Olufade TO, Ramey DR, et al. Gender disparities in lipid‐lowering therapy in cardiovascular disease: insights from a managed care population. J Womens Health (Larchmt) 2016; 25: 697‐706.
No relevant disclosures.